Sobre la importancia de programas específicos de optimización de antibioterapia (PROA) en oncología… jamanetwork.com/journals/jam...

Part 1 of a two-part series on outpatient antimicrobial stewardship interventions in immunocompromised patients: what has been studied, what are barriers to implementing interventions in this group, and how ASPs might overcome these challenges. doi.org/10.1017/ash....

Remdesivir and a monoclonal antibody (MBP134) will be tested against SOC. www.who.int/news/item/02... #IDsky Amazing PARTNERS initiative. Being able to run an adaptive platform trial in this situation is so needed and yet so impressive. Hats off for the team! @who.int

A (not so) new kid on the block! Temocillin proved non-inferior to carbapenems against 3GR-Enterobacterales. Hope to see this old drug widely available in Europe soon! 🤞🏻 www.thelancet.com/journals/lan... #AMSsky #IDsky

Disappointing data on meningitis vaccine preventing Neisseria gonorrhoea infections Then again negative trial data is as useful as positive findings, so that we focus resources most effectively #IDSky www.nejm.org/doi/full/10....

Nurses boost AMS! #UTIsky #AMSsky

Immunocompromised hosts should not be excluded from duration trials. The question is how we can safely incorporate them into these studies to generate the evidence we need. Our editorial in @cmijournal.bsky.social is freely available here: 🔓 authors.elsevier.com/a/1nOm-,RGPg... #IDsky #TxID #IDOnc

EcoRxChoice 🌍💊 lets users compare plastic waste from antimicrobial regimens, promoting eco-friendly prescribing. Supported by SIDP to boost sustainable antimicrobial stewardship.

🌟 The 2025 JCR Impact Factor for CMI has risen to 8.7! We thank our editors, reviewers, authors and readers for their dedication and extraordinary work. Read about how CMI did in 2025 here: clinicalmicrobiologyandinfection.org/article/S119... #IDSky #MicroSky #JIF #JCR2025

𝐍𝐞𝐰 𝐢𝐧 𝑵𝑬𝑱𝑴 𝑪𝒂𝒕𝒂𝒍𝒚𝒔𝒕 𝑰𝒏𝒏𝒐𝒗𝒂𝒕𝒊𝒐𝒏𝒔 𝒊𝒏 𝑪𝒂𝒓𝒆 𝑫𝒆𝒍𝒊𝒗𝒆𝒓𝒚! HealthPartners’ Antimicrobial Stewardship Program demonstrates the potential of centralized complex outpatient antibiotic therapy programs to optimize patient care. Learn more: https://nej.md/4uEs79k Explore the July issue: https://nej.md/3QMDUo2

We are genotyping and phenotyping the SNAP MSSA isolates for cefazolin inoculum effect. So we can look at cefazolin vs ASPs (randomized) treatment effect in CIE+, and compare to that in CIE-. I estimate several hundred (prob >400) in each CIE group.

Looking for a new antimicrobial stewardship metric? 👀 Authors from the VA have proposed a new "S3" option, which assesses the initiation, spectrum, and duration of therapy. 📖 Read more here academic.oup.com/cid/advance-... #AntimicrobialStewardship

The implications of this work is that we need look into body compartments to understand the inflammatory responses and can't simply rely on blood. Further, we need to tailor our treatments to the mechanisms identified- a simple "pneumonia=treatment X" is not going to work.

Great to see our new paper out in Nature Communications. In it we describe three novel phenotypes in lungs of patients with pneumonia. Pn1 -a non-neutrophil driven lung injury phenotype, Pn2-a balanced immune response with best recovery and Pn3-persistent inflammation driven by immature neutrophils

Good news: C difficile diarrhea cases are decreasing in hospitals due to decreased antibiotic use Bad news: C difficile is increasing in the community, possibly due to widespread use of antibiotics in agriculture #IDSky

The OASIS RCT comparing olorofim vs amphotericin B for azole-resistant aspergillosis met its primary endpoint of non-inferiority for mortality (23% vs 24%), with fewer AEs (36% vs 64%), according to company report: www.shionogi.com/global/en/ne... Looking forward to the publication! #IDsky #IDOnc

Bringing #AMR into the outcome assessment of duration trials with the new DOOR-FRAME is very welcome! Larger samples and systematic AMR assessment among participants will be likely required to prove benefit academic.oup.com/ofid/article... #IDSky #AMSsky Awesome work by @seanong.bsky.social et al

Plastic pollution is pervasive across ecosystems. A Review in Nature Reviews Biodiversity summarizes current evidence on plastic exposure pathways, organismal responses and potential effects at higher levels of biological organization. go.nature.com/3QsA6rS 🌎🧪

Not all apples to apples. Editorial for this piece with a nice summary of available evidence for fosfomycin academic.oup.com/cid/advance-...

Antimicrobial Stewardship [vol.2] already running! Did we miss someone? 😉 #AMSsky #IDsky #MicroSky #PharmSky go.bsky.app/2qsEveQ

How could we define the best treatment duration for immunocompromised hosts? Happy to share our perspective in this editorial in @cmijournal.bsky.social, building on the recent BALANCE subanalysis for this vulnerable population www.sciencedirect.com/science/arti... #AMSsky #TxID #IDOnc #IDsky

The #FDA has approved #tebipenem pivoxil the first oral carbapenem antibiotic in the US for adults with complicated urinary tract infections. #IDsky #Medsky www.contagionlive.com/view/fda-app...

Wow! 🆕🔥🔴Multicenter OL NI RCT Oral fosfomycin (3 g once daily) was noninferior to continued intravenous therapy with carbapenems or BLBLIs when used as oral transition therapy for complicated UTIs caused by ESBL-producing Enterobacterales #IDSky #utisky academic.oup.com/cid/article-...

The SNAP trial domain on cefazolin vs cloxacillin for MSSA bacteremia is finally published! www.nejm.org/doi/full/10.... Cefazolin is already the new standard! #IDsky #AMSsky

🎙️ Just published Communicable E56: Frequentist vs Bayesian for clinical trial analysis – 99% probability you’ll want to listen to this Hosted by Emily McDonald & Josh Davis with invited guests Roger Lewis & Ian Marschner 🌟 Listen on #Communicable: https://share.transistor.fm/s/7ea020d2#Communicable #IDSky

📣 If you have questions about fosfomycin, we have answers! Excellent review article by Tiffany Wu, Kalpana Gupta, @erinmccreary.bsky.social, Sarah Turbett & Jacob Lazarus on oral #fosfomycin & how to use it. #IDSky #clinmicro #UTISky #Medsky #Pharmsky www.cmi-comms.org/article/S295...

There’s enough evidence from observational and RCT subgroups to stop excluding systematically immunocompromised hosts from duration trials. Uncomplicated source + early response should always mean shorter. 1 in 3 patients in @shorten2trial.bsky.social is inmunocompromised bsky.app/profile/jose...

Excited to share an article that I've long awaited to share seeking to answer: What is the right dose of cephalexin/cefadroxil for SSTIs? We reviewed clinical studies & conducted PTA sims to elucidate this #IDSky @absteward.bsky.social accpjournals.onlinelibrary.wiley.com/doi/10.1002/...

REMAP-CAP domain on oseltamivir vs no-antiviral for patients admitted at ICU with influenza is stopped due to potential harm! 90d mortality: Oseltamivir=19.4% (62/319) No antiviral=13.7% (17/124) Last word for oseltamvir? What’s the rationale for harm? #IDSky www.remapcap.org/oseltamivir-...

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://nej.md/4nWaxvM #ASCO26

Cefepime/Zidebactam: Class: DBO Inhibitor + 4th-Gen Cephalosporin Potent PBP2 “Enhancer Effect". Broad serine beta-lactamases and complementary PBP binding against MBLs Demonstrated success in compassionate-use salvage therapy for extensively drug-resistant, NDM-producing P. aeruginosa #idsky

SHORTEN2 results have been presented at #CongresoSEIMC2026! 7-day treatments were shown superior to 14-day in reducing antibiotic exposure and adverse events while maintaining efficacy. Fantastic work by >100 researchers across 37 Spanish hospitals! #TeamPride #IDsky #AMSsky @seimc.bsky.social

Amazing 😍 🔥SHORTEN 2 RCT A 7-day treatment course is superior to 14 days for uncomplicated Pseudomonas aeruginosa bacteremia, achieving similar clinical response rates with lower antibiotic exposure, fewer superinfections, and fewer serious adverse events #idsky @shorten2trial.bsky.social

We’re happy to share that results of the @shorten2trial.bsky.social will be presented at the #XXIXCongresoSEIMC! 📆 Friday, May 29 - 14:25h 📍Room 0D 📻 Stay tuned! #AMSsky #IDSky @absteward.bsky.social @idstewardship.bsky.social @bradspellberg.bsky.social @drtoddlee.bsky.social @esgap.bsky.social

ESCMID 2026 highlights COBRA Trial – One day is enough Dutch RCT: 1 day of antibiotics after ERCP drainage for cholangitis was non‑inferior to 4–7 days. Bottom line: Antibiotic durations can safely be much shorter once source control is achieved. #IDSky clarityinitiative.org/escmid-2026-...

📣The Guidelines Subcommittee has an open call to train young professionals in guidelines production. It's free of charge, but participants commit to support projects after completing the course. https://ow.ly/lIyy50Z31c9 ⏰Apply by Friday! #IDSky #clinmicro

Can we use short treatments for bacteremia in #SOT? This metaanalysis of observational data + SOT randomized in prior trials suggests the efficacy of short courses. We’ve got the rationale to stop excluding SOT from duration trials! onlinelibrary.wiley.com/doi/10.1111/... #IDSky #AMSsky #TxID

🆕💥🟢A contaminated dicloxacillin capsules in Europe triggered not only a clonal NDM-5/OXA-48 Enterobacter hormaechei outbreak, but also plasmid transfer to other Enterobacterales. Many cases were missed by standard strain-based outbreak methods #idsky #microsky www.thelancet.com/journals/lan...

📣We are now accepting applications for ESCMID Study Group research grants! Joining a study group is free and open to all ESCMID members. Our study groups cover a vast range topics eligible for funding. Propel your research to new heights! 💡Learn more: https://ow.ly/68VQ50Z23gP #IDSky #clinmicro

🆕💥🔴Integral-1 RCT Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis #idsky www.thelancet.com/journals/lan...

Not all β-lactamases are equal. Know your β-lactamase → Ambler classification made simple—in one image #IDSky #microsky Ref: www.mdpi.com/2079-6382/10...

OpenEvidence is no longer available in EU/UK due to regulatory uncertainty & liability concerns Withdrawal is business decision, but mobilizing users to pressure policymakers for economic interests is worrying. Europe should build its alternative. Know other options #IDSky #MedSky? Please share!👇🧵

📣The Guidelines Subcommittee has an open call to train young professionals in guidelines production. It's free of charge, but participants commit to support projects after completing the course. https://ow.ly/jzov50YOuQl ⏰Apply by 29 May! @luigiascudeller.bsky.social #IDSky #clinmicro

Take-home message at #ESCMIDGlobal2026: 💊 Overprescribing antibiotics costs the EU ~€2.7B annually 💶 Fixing it costs ~€107M 📉 Net savings: €151M–€423M AMR stewardship isn’t a cost—it’s a high-yield investment.

It’s been great to see #IDSky so active during #ESCMIDGlobal2026 Thanks so much to @escmid.bsky.social ambassadors to keep Bluesky community in mind! @absteward.bsky.social @idstewardship.bsky.social @drneilstone.bsky.social @krutikakuppalli.bsky.social Fantastic initiative, let’s keep it going!

It will be published soon. Both the MSSA silo and PSSA silo, which both included (flu)cloxacillin, found NI on 90 day mortality for cefazolin (or penicillin) and lower rates of AKI compared to (flu)cloxacillin. The AKI mostly defined by increase in creatinine of at least 1.5x.

Important piece of work that guides much of our OPAT practice in UK. It's also impressive in its acceptance of the evidence. Literally the guideline for use of IV antibiotics is advocating for use of oral antibiotics instead! 👏 #IDSky #ClinMicro #AMR #OPAT

During #EndoORAL trial presentation #ESCMIDGlobal2026, a key question was raised: was cardiac imaging (echo /TEE) performed before switching to oral therapy as per ESC 2023 recommendations? The presenter replied: no, it was not routinely done! #idsky

🔥Late Breakers PeterPen RCT prelim results challenges carbapenem default in ESBL BSI Pip/tazo vs MER (EI) ✅Non-inferior 7d failure(29.4% vs 33.5%) ❌No early mortality signal 30d mortality 14.4%(interim) 👉Will mortality follow?MERINO taught us the hard way! #ESCMIDGlobal2026 #IDsky